亚辉龙(688575) - 2021 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2021 reached ¥309,120,920.20, an increase of 10.28% year-over-year, while year-to-date revenue was ¥857,127,530.33, up 20.90% compared to the same period last year[8] - Net profit attributable to shareholders for Q3 2021 was ¥66,387,457.14, reflecting a 37.16% increase year-over-year, with year-to-date net profit at ¥154,949,087.08, a 3.92% increase[8] - Total operating revenue for the first three quarters of 2021 reached ¥857,127,530.33, an increase from ¥708,961,636.60 in the same period of 2020, representing a growth of approximately 20.9%[36] - Net profit for the first three quarters of 2021 was ¥156,576,131.19, compared to ¥147,433,755.99 in 2020, indicating an increase of approximately 6.9%[39] - The company reported a net profit of ¥508,126,642.13 for the period, compared to ¥353,177,555.05 in the previous year, indicating an increase of about 44%[32] Research and Development - R&D expenditure totaled ¥35,344,590.57 in Q3 2021, representing 11.43% of revenue, with a year-to-date total of ¥103,427,658.79, which is 42.12% higher than the previous year[12] - The company plans to continue increasing R&D investments to enhance long-term core competitiveness and expand its product portfolio[15] - Research and development expenses rose to ¥99,439,979.48 in 2021 from ¥72,775,494.29 in 2020, marking an increase of about 36.6%[36] Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to ¥1,954,991,159.46, a 47.72% increase from the end of the previous year, primarily due to funds raised from the IPO on May 17, 2021[12] - Total non-current assets reached ¥740,671,801.56, compared to ¥529,542,410.59 at the end of 2020, indicating a growth of approximately 40%[30] - The company's total assets amounted to ¥1,954,991,159.46, up from ¥1,323,422,336.84, reflecting an increase of around 48%[32] - Total liabilities decreased to ¥493,183,201.47 from ¥559,445,499.36, showing a reduction of about 12%[32] - Total liabilities included short-term borrowings of ¥302,000,000.00, unchanged from the previous year[50] Shareholder Information - Shareholders' equity attributable to shareholders reached ¥1,463,995,550.01, a significant increase of 90.68% compared to the previous year, also driven by the IPO[12] - The top ten shareholders hold a combined 66.93% of the shares, with the largest shareholder owning 39.18%[19] - The company's equity attributable to shareholders increased to ¥1,463,995,550.01 from ¥767,791,473.61, representing a growth of approximately 91%[32] Cash Flow - The company reported a net cash flow from operating activities of ¥128,618,357.59 year-to-date, which is a decrease of 18.44% compared to the previous year[12] - Cash flow from operating activities generated ¥928,188,403.66 in 2021, up from ¥733,479,807.10 in 2020, showing an increase of approximately 26.6%[42] - Operating cash inflow totaled ¥960,251,099.33, an increase from ¥773,119,501.20 year-over-year[46] - Cash inflow from financing activities reached ¥836,120,567.68, up from ¥671,941,101.49 in the previous year[48] - Net cash flow from financing activities was ¥438,545,874.84, significantly higher than ¥18,318,321.08 in the previous year[48] Inventory and Operating Costs - The inventory level rose to ¥370,327,859.59 from ¥298,164,851.13, which is an increase of approximately 24%[26] - Total operating costs increased to ¥689,417,603.09 in 2021 from ¥544,133,770.99 in 2020, reflecting a rise of about 26.6%[36] Other Financial Information - The company experienced a steady increase in instrument installation and hospital consultations, contributing to revenue and gross margin growth post-pandemic[15] - The company has not disclosed any new product or technology developments during this reporting period[26] - There are no significant market expansion or acquisition strategies mentioned in the report[26] - The company reported a decrease in financial expenses from ¥12,180,686.42 in 2020 to ¥7,512,646.02 in 2021, a reduction of approximately 38.8%[36] - Other income decreased to ¥14,678,042.88 in 2021 from ¥24,270,118.96 in 2020, a decline of about 39.5%[36]